Development of artemisinin resistance in malaria therapy

Publication type:
Journal article
Metadata:
Autoren
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000482248300034&DestLinkType=FullRecord&DestApp=WOS_CPL
DOI
10.1016/j.phrs.2019.104275
eISSN
1096-1186
Externe Identifier
  • Clarivate Analytics Document Solution ID: IS6FS
  • PubMed Identifier: 31100335
ISSN
1043-6618
Zeitschrift
PHARMACOLOGICAL RESEARCH
Schlüsselwörter
  • Malaria
  • Resistance
  • Mutation
  • Artemisinin
  • Artemisinin combination therapy
Artikelnummer
ARTN 104275
Datum der Veröffentlichung
2019
Status
Published
Titel
Development of artemisinin resistance in malaria therapy
Sub types
  • Review
Ausgabe der Zeitschrift
146

Data source: Web of Science (Lite)

Other metadata sources:
Autoren
DOI
10.1016/j.phrs.2019.104275
ISSN
1043-6618
Zeitschrift
Pharmacological Research
Sprache
en
Artikelnummer
104275
Paginierung
104275 - 104275
Datum der Veröffentlichung
2019
Status
Published
Herausgeber
Elsevier BV
Herausgeber URL
http://dx.doi.org/10.1016/j.phrs.2019.104275
Datum der Datenerfassung
2020
Titel
Development of artemisinin resistance in malaria therapy
Ausgabe der Zeitschrift
146

Data source: Crossref

Abstract
Malaria affects 200 million people worldwide. Today, the most successful treatments are artemisinin-based combination therapies (ACT). Resistance has already been described for the elder anti-malarials chloroquine, sulfadoxine-pyrimethamine and mefloquine. Unfortunately, over the last few years there has also been an emerging resistance to the successfully used drug artemisinin, especially in African and Asian countries. A systematic PubMed literature research was conducted for studies published between January 2002 and December 2018. Despite ACTs continue to be first line treatment, the number of studies is rising reporting on artemisinin resistance mutations. Most publications reported on kelch13 mutations (45 studies), the second most frequent mutations were found in pfmdr1 (32 studies). PfATPase6 mutations have been mainly studied in Asian countries (4 of 6 studies). Bearing this in mind, there is a pressing need to further examine the role and spread of mutations conferring artemisinin resistance. A further decline of treatment efficacy could result in increased rates of malaria-related deaths.
Addresses
  • Department of Pharmaceutical Biology, Institute of Biochemistry and Pharmacy, Johannes Gutenberg University, Staudinger Weg 5, 55128 Mainz, Germany.
Autoren
DOI
10.1016/j.phrs.2019.104275
eISSN
1096-1186
Externe Identifier
  • PubMed Identifier: 31100335
Funding acknowledgements
  • Deutsche Forschungsgemeinschaft: DFG GRK 2015/1
Open access
false
ISSN
1043-6618
Zeitschrift
Pharmacological research
Schlüsselwörter
  • Animals
  • Humans
  • Malaria
  • Artemisinins
  • Antimalarials
  • Drug Resistance
  • Mutation
  • Polymorphism, Genetic
Sprache
eng
Medium
Print-Electronic
Online publication date
2019
Paginierung
104275
Datum der Veröffentlichung
2019
Status
Published
Datum der Datenerfassung
2019
Titel
Development of artemisinin resistance in malaria therapy.
Sub types
  • Research Support, Non-U.S. Gov't
  • Systematic Review
  • Journal Article
Ausgabe der Zeitschrift
146

Data source: Europe PubMed Central

Abstract
Malaria affects 200 million people worldwide. Today, the most successful treatments are artemisinin-based combination therapies (ACT). Resistance has already been described for the elder anti-malarials chloroquine, sulfadoxine-pyrimethamine and mefloquine. Unfortunately, over the last few years there has also been an emerging resistance to the successfully used drug artemisinin, especially in African and Asian countries. A systematic PubMed literature research was conducted for studies published between January 2002 and December 2018. Despite ACTs continue to be first line treatment, the number of studies is rising reporting on artemisinin resistance mutations. Most publications reported on kelch13 mutations (45 studies), the second most frequent mutations were found in pfmdr1 (32 studies). PfATPase6 mutations have been mainly studied in Asian countries (4 of 6 studies). Bearing this in mind, there is a pressing need to further examine the role and spread of mutations conferring artemisinin resistance. A further decline of treatment efficacy could result in increased rates of malaria-related deaths.
Date of acceptance
2019
Autoren
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/31100335
DOI
10.1016/j.phrs.2019.104275
eISSN
1096-1186
Zeitschrift
Pharmacol Res
Schlüsselwörter
  • Artemisinin
  • Artemisinin combination therapy
  • Malaria
  • Mutation
  • Resistance
  • Animals
  • Antimalarials
  • Artemisinins
  • Drug Resistance
  • Humans
  • Malaria
  • Mutation
  • Polymorphism, Genetic
Sprache
eng
Country
Netherlands
Paginierung
104275
PII
S1043-6618(19)30474-8
Datum der Veröffentlichung
2019
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2020
Titel
Development of artemisinin resistance in malaria therapy.
Sub types
  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Systematic Review
Ausgabe der Zeitschrift
146

Data source: PubMed

Beziehungen:
Property of

Tools